provided they have been failures on conventional modes of treatment for their 
disease. 
5.2 Patients must have a life expectancy of at least 8 weeks. 
5.3 Patients or legal guardians must sign an informed consent indicating that they 
are aware this is a research study and have been told of its possible benefits 
and toxic side effects. Patients or their guardians will be given a copy of the 
consent form. 
5.4 Patients must have recovered from the toxic effects of all prior chemotherapy 
before entering this study, and have an absolute neutrophil count of > 500/mm 3 
and platelet count > 50,000/mm 3 (unless bone marrow is replaced by tumor). 
5.5 Patients must not be infected at time of protocol entry, and should not be 
receiving antibiotics (other than prophylactic Septra). 
5.6 Patients must not be HIV-positive. 
5.7 Patients must have adequate liver function (bilirubin <1.5 mg%, normal 
prothrombin time). 
5.8 Patients must have adequate renal function (creatinine <1.5 mg% or 
creatinine clearance, >80 ml/min/1.73 m 2 ) and normal metabolic parameters 
(serum electrolytes, blood sugar, calcium, phosphorous). 
5.9 Urinalysis must be normal at time of entry to study. 
5.10 Patients must have normal nutritional status (weight > 10th percentile for age, 
serum albumin >3 gm/dl) and Performance Status (ECOG) of 0-2. 
5.9.1 Performance Status Definition 
ECOG 
Karnofsky 
Grade 
Score 
Activitv 
0 
90-100 
Up and about, no restriction. 
1 
70-90 
Ambulatory, no strenuous activity. 
[752] 
Recombinant DNA Research, Volume 15 
